EXTRAORDINARY GENERAL MEETING OF SIKA AG - SHAREHOLDERS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
30
EXTRAORDINARY GENERAL MEETING OF SIKA AG - SHAREHOLDERS APPROVE ALL PROPOSALS OF THE BOARD OF DIRECTORS

At today's Extraordinary General Meeting of Sika AG the shareholders have approved by a large majority all proposals of the Board of Directors. In particular the following resolutions were taken:

  • The creation of unitary registered shares with a nominal value of CHF 0.01 each, the abolishment of the opting-out and the transfer restrictions as well as the cancellation of the Sika registered shares purchased from Schenker-Winkler Holding AG (representing 6.97% of the share capital) by way of a capital reduction in an amount of CHF 106,295.20 to CHF 1,417,811.60 were approved.
  • Justin Howell was elected as a member of the Board of Directors and of the Nomination and Compensation Committee.
  • The compensation of the Board of Directors for the terms of office from the Annual General Meeting 2015 to the Annual General Meeting 2019 was approved.
  • The administrative bodies were granted unconditional discharge.
  • The special experts committee established by the Annual General Meeting 2015 was withdrawn.

CONTACT Dominik Slappnig Corporate Communications and Investor Relations +41 58 436 68 21 slappnig.dominik@ch.sika.com

SIKA CORPORATE PROFILE Sika is a specialty chemicals company with a leading position in the development and production of systems and products for bonding, sealing, damping, reinforcing and protecting in the building sector and motor vehicle industry. Sika has subsidiaries in 101 countries around the world and manufactures in over 200 factories. Its more than 18,000 employees generated annual sales of CHF 6.25 billion in 2017.

The media release can be downloaded from the following link:

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading